Testing effectiveness (Phase 2)Study completedNCT01193907
What this trial is testing
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
Who this might be right for
Typhoid Fever
Novartis 88